Thursday, 9 February 2017

Lupin Q3: Cons


PAT At Rs 633 Cr Vs CNBC-TV18 Poll Of Rs 609.5 Cr;

Rev At Rs 4483 Cr Vs CNBC-TV18 Poll Of Rs 4239 Cr

EBITDA At Rs 1,215.8 Cr Vs CNBC-TV18 Poll Of Rs 1,011.7 Cr;

Margin At 27.1% Vs CNBC-TV18 Poll Of 24%

US Sales Up 53.4% At $316 m Vs $206 m;

India Formulation Sales Up 11.9% At Rs 991.2 Cr Vs Rs 886 Cr

Asia-Pacific Sales Up 20.9% At Rs 560 Cr Vs Rs 463.4 Cr;

EMEA Sales Up 16.8% At Rs 255.5 Cr Vs Rs 218.7 Cr

North America Sales Up 57.6% At Rs 2,175.5 Cr Vs Rs 1,380.5 Cr

No comments:

Post a Comment